NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-08-31
Reading WST? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
West Pharma makes parts for injectable drugs. Sales grew 21% last year. The company expects $3.3 billion revenue in 2026. Earnings per share should be about $8.57 in 2026.
Growth could slow below 7%. Rising costs might cut profit margins. CEO change may cause uncertainty.
The price is about 35% above our fair value near $265. Analysts expect 6.5% revenue growth, but we see slower growth ahead.
Breaks if: EPS falls below $8.0 in FY26
Breaks if: Q2 EPS falls below $2.0
Breaks if: revenue falls below $3.1 billion in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
WST represents a durable compounder in the healthcare sector. The current thesis is intact, supported by strong financial performance and management's focus on revenue and earnings growth.
The market currently prices WST at an expensive valuation compared to its peers, reflecting a durable premium. There is an expectations gap, indicating that the market anticipates continued strong performance.
Management has consistently raised revenue and earnings guidance, indicating a strong fundamental trajectory. However, there is moderate risk due to potential economic headwinds and the company's recent history of missing expectations.
The long-term thesis hinges on maintaining positive momentum in the healthcare sector and the company's ability to meet or exceed its guidance. Key factors include the performance of sector bellwethers and overall economic conditions.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports increased revenue and EPS guidance. This positive outlook reinforces confidence in the company's growth potential.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
WST's strong recent performance and management execution support its long-term thesis, but valuation concerns and external risks warrant careful observation. Not investment advice.
